Denosumab

0 marketed 2 in Phase 3

This page covers all Denosumab drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting RANKL.

Targets

Phase 3 pipeline (2)

US-licensed Prolia (Amgen) · Fresenius Kabi SwissBioSim GmbH · Osteoporosis
Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.
US-licensed Prolia · Celltrion · Osteoporosis
Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.